Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRIO NASDAQ:HYPR NYSE:NSPR NASDAQ:OBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$9.51-6.6%$12.01$7.60▼$31.00$21.63M1.1114,804 shs4,256 shsHYPRHyperfine$1.24$1.04$0.53▼$1.90$97.44M1.07368,886 shs118,010 shsNSPRInspireMD$2.44+0.8%$2.42$1.99▼$3.80$101.80M0.6103,146 shs32,601 shsOBIOOrchestra BioMed$2.73+0.7%$2.86$2.37▼$7.04$105.50M0.62421,235 shs123,956 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth0.00%-16.59%-13.53%-32.08%-41.30%HYPRHyperfine0.00%-4.25%+20.39%+45.88%+22.77%NSPRInspireMD0.00%+2.52%-9.29%-3.94%-11.27%OBIOOrchestra BioMed0.00%+7.06%+11.89%-13.61%-59.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRIODarioHealth1.7119 of 5 stars3.30.00.00.02.40.81.3HYPRHyperfine1.6083 of 5 stars1.35.00.00.03.51.70.6NSPRInspireMD3.3169 of 5 stars3.55.00.00.00.64.20.6OBIOOrchestra BioMed3.4421 of 5 stars3.55.00.00.04.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRIODarioHealth 2.67Moderate Buy$40.00320.61% UpsideHYPRHyperfine 2.67Moderate Buy$1.283.49% UpsideNSPRInspireMD 3.00Buy$4.5084.43% UpsideOBIOOrchestra BioMed 3.00Buy$14.00412.82% UpsideCurrent Analyst Ratings BreakdownLatest DRIO, HYPR, NSPR, and OBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025OBIOOrchestra BioMedBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/15/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$0.68 ➝ $0.858/14/2025HYPRHyperfineLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $2.008/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.008/7/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRIODarioHealth$27.04M0.80N/AN/A$42.24 per share0.23HYPRHyperfine$12.89M7.56N/AN/A$0.67 per share1.85NSPRInspireMD$7.07M14.41N/AN/A$1.83 per share1.33OBIOOrchestra BioMed$2.64M39.96N/AN/A$0.87 per share3.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRIODarioHealth-$42.75M-$13.20N/AN/AN/A-162.73%-65.89%-39.03%11/6/2025 (Estimated)HYPRHyperfine-$40.72M-$0.52N/AN/AN/A-364.54%-84.82%-69.39%11/11/2025 (Estimated)NSPRInspireMD-$19.92M-$0.83N/AN/AN/A-413.96%-69.42%-57.68%N/AOBIOOrchestra BioMed-$61.02M-$1.83N/AN/AN/A-2,367.49%-289.42%-110.04%11/11/2025 (Estimated)Latest DRIO, HYPR, NSPR, and OBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$3.00 million$2.70 million8/12/2025Q2 2025OBIOOrchestra BioMed-$0.51-$0.50+$0.01-$0.50$0.78 million$0.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRIODarioHealthN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRIODarioHealth0.483.302.83HYPRHyperfineN/A5.024.41NSPRInspireMDN/A6.396.05OBIOOrchestra BioMed48.762.102.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRIODarioHealth33.39%HYPRHyperfine15.03%NSPRInspireMD44.78%OBIOOrchestra BioMed53.20%Insider OwnershipCompanyInsider OwnershipDRIODarioHealth11.20%HYPRHyperfine30.98%NSPRInspireMD34.06%OBIOOrchestra BioMed8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRIODarioHealth2002.27 million2.02 millionOptionableHYPRHyperfine19078.58 million54.24 millionOptionableNSPRInspireMD5041.72 million18.33 millionOptionableOBIOOrchestra BioMed438.64 million35.51 millionNot OptionableDRIO, HYPR, NSPR, and OBIO HeadlinesRecent News About These CompaniesOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Average Rating of "Buy" from AnalystsSeptember 1 at 2:41 AM | marketbeat.comInsider Buying: Orchestra BioMed (NASDAQ:OBIO) Insider Acquires 6,000 Shares of StockAugust 27, 2025 | marketbeat.comOrchestra BioMed (NASDAQ:OBIO) Director Purchases $15,033.60 in StockAugust 27, 2025 | marketbeat.comOrchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure ...August 26, 2025 | bakersfield.comBOrchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical ElectrophysiologyAugust 26, 2025 | globenewswire.comInsider Buying: Orchestra BioMed (NASDAQ:OBIO) Insider Acquires 6,000 Shares of StockAugust 26, 2025 | insidertrades.comOrchestra BioMed (NASDAQ:OBIO) Given "Neutral" Rating at BTIG ResearchAugust 22, 2025 | marketbeat.comBTIG Downgrades Orchestra BioMed Holdings (OBIO)August 21, 2025 | msn.comOrchestra BioMed (NASDAQ:OBIO) Receives "Neutral" Rating from BTIG ResearchAugust 21, 2025 | americanbankingnews.comOrchestra BioMed downgraded to Neutral from Buy at BTIGAugust 20, 2025 | msn.comOrchestra BioMed Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comEquities Analysts Offer Predictions for OBIO FY2025 EarningsAugust 19, 2025 | marketbeat.comOrchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart DiseaseAugust 17, 2025 | msn.comOrchestra BioMed (NASDAQ:OBIO) Given "Buy" Rating at Chardan CapitalAugust 15, 2025 | marketbeat.comOrchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA MilestonesAugust 15, 2025 | msn.comOrchestra BioMed (NASDAQ:OBIO) Issues Earnings Results, Beats Estimates By $0.01 EPSAugust 14, 2025 | marketbeat.comOrchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic DysfunctionAugust 14, 2025 | globenewswire.comOrchestra BioMed reports Q2 EPS (50c), consensus (51c)August 12, 2025 | msn.comOrchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue EstimatesAugust 12, 2025 | zacks.comOrchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business UpdatesAugust 12, 2025 | finanznachrichten.deOrchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business UpdatesAugust 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRIO, HYPR, NSPR, and OBIO Company DescriptionsDarioHealth NASDAQ:DRIO$9.51 -0.67 (-6.58%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.46 -0.05 (-0.58%) As of 08/29/2025 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Hyperfine NASDAQ:HYPR$1.24 0.00 (0.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.23 -0.01 (-0.73%) As of 08/29/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.InspireMD NYSE:NSPR$2.44 +0.02 (+0.83%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.44 0.00 (0.00%) As of 08/29/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Orchestra BioMed NASDAQ:OBIO$2.73 +0.02 (+0.74%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.76 +0.03 (+1.10%) As of 08/29/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
